NCT06857214View on ClinicalTrials.gov

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

GNC-038

Administration by intravenous infusion. Once a week (IV, QW), twice in total.

DRUG

Placebo

The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.

Trial Locations (1)

Unknown

RECRUITING

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT06857214 - A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter